Analysts at Bernstein are out with a report this morning upgrading shares of Biogen Inc. (BIIB) with a ‘Outperform‘ from ‘Market Perform‘ rating. The firm however, lowered its price target for the company to $385 from $436 noting shares have succumbed to a perfect storm of slower earnings growth, reduced guidance and pipeline concerns. Biogen […] View the full post at: Notable Upgrades: Biogen (BIIB), Qualcomm (QCOM), Teva (TEVA), Expedia Inc. (EXPE), Comcast (CMCSA) Related posts: Cramer Sees No Catalyst for Comcast (CMCSA) Strategic Overhang Sinks Comcast Following Strong Quarter Nokia Settles with Qualcomm for $2.3 bln in Patent Agreement